Expression of Murine Interleukin 7 in a Murine Glioma Cell Line Results in Reduced Tumorigenicity in Vivo

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1992 May 1

PMID 1570303

Citations 28

Authors

T Aoki

K Tashiro

S Miyatake

T Kinashi

T Nakano

Y Oda

H Kikuchi

T Honjo

Affiliations

Soon will be listed here.

Abstract

We have examined the immunoregulatory effect of local and continuous secretion of interleukin 7 (IL-7) from murine glioma cells (203-glioma) engineered by murine IL-7 gene transfection. Secretion of IL-7 from glioma cells did not result in morphology or growth rate changes but did reduce tumorigenicity in vivo in proportion to the amount of IL-7 produced. This reduction in tumorigenicity could be reversed in a dose-dependent fashion by injection of anti-IL-7 neutralizing monoclonal antibody at the tumor site. Mice immunized with IL-7-producing glioma cells showed a specific immune response to 203-glioma but not to two other syngeneic cell lines (B-16, a melanoma, and YM-12, a fibrosarcoma). IL-7-producing glioma cells were not rejected in mice depleted of CD8+ cells but were rejected in mice depleted of CD4+ or NK1.1+ cells. These results suggest that CD8+ T cells may play an important role in tumor rejection.

Citing Articles

Tumor cells ectopically expressing the membrane-bound form of IL-7 develop an antitumor immune response efficiently in a colon carcinoma model.

Shin H, Kim H, Kwon S, Lee H, Lee J, Kim Y Mol Cells. 2025; 48(2):100175.

PMID: 39743142 PMC: 11873615. DOI: 10.1016/j.mocell.2024.100175.

Glioblastoma cellular MAP4K1 facilitates tumor growth and disrupts T effector cell infiltration.

Sun J, Fan H, Zhu Y, Pan T, Wu Y, Zhang D Life Sci Alliance. 2023; 6(12).

PMID: 37734869 PMC: 10514360. DOI: 10.26508/lsa.202301966.

Interleukin (IL)-7 Signaling in the Tumor Microenvironment.

Bednarz-Misa I, Bromke M, Krzystek-Korpacka M Adv Exp Med Biol. 2021; 1290:9-49.

PMID: 33559853 DOI: 10.1007/978-3-030-55617-4_2.

Functional Change of Effector Tumor-Infiltrating CCR5CD38HLA-DRCD8 T Cells in Glioma Microenvironment.

Chen P, Wu C, Fang J, Chen H, Feng L, Huang C Front Immunol. 2019; 10:2395.

PMID: 31649684 PMC: 6794477. DOI: 10.3389/fimmu.2019.02395.

A human recombinant IL-7/HGFβ hybrid cytokine enhances antitumor immunity in mice.

Han F, Hu R, Su M, Yu Y, Yang H, Lai L Am J Cancer Res. 2017; 7(8):1714-1723.

PMID: 28861327 PMC: 5574943.

References

Potter H, Weir L, Leder P . Enhancer-dependent expression of human kappa immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation. Proc Natl Acad Sci U S A. 1984; 81(22):7161-5. PMC: 392097. DOI: 10.1073/pnas.81.22.7161. View

Larsson I, Landstrom L, Larner E, Lundgren E, Miorner H, Strannegard L . Interferon production in glia and glioma cell lines. Infect Immun. 1978; 22(3):786-9. PMC: 422229. DOI: 10.1128/iai.22.3.786-789.1978. View

de Martin R, Haendler B, Hofer-Warbinek R, Gaugitsch H, Wrann M, Schlusener H . Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family. EMBO J. 1987; 6(12):3673-7. PMC: 553836. DOI: 10.1002/j.1460-2075.1987.tb02700.x. View

Cobbold S, Martin G, Qin S, Waldmann H . Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature. 1986; 323(6084):164-6. DOI: 10.1038/323164a0. View

Rosenstein M, Ettinghausen S, Rosenberg S . Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol. 1986; 137(5):1735-42. View

Nishimura T, Togashi Y, Goto M, Yagi H, Uchiyama Y, Hashimoto Y . Augmentation of the therapeutic efficacy of adoptive tumor immunotherapy by in vivo administration of slowly released recombinant interleukin 2. Cancer Immunol Immunother. 1986; 21(1):12-8. PMC: 11038665. DOI: 10.1007/BF00199371. View

Koo G, Dumont F, TUTT M, Hackett Jr J, Kumar V . The NK-1.1(-) mouse: a model to study differentiation of murine NK cells. J Immunol. 1986; 137(12):3742-7. View

Frei K, Bodmer S, Schwerdel C, Fontana A . Astrocytes of the brain synthesize interleukin 3-like factors. J Immunol. 1985; 135(6):4044-7. View

Lang R, Metcalf D, Gough N, Dunn A, Gonda T . Expression of a hemopoietic growth factor cDNA in a factor-dependent cell line results in autonomous growth and tumorigenicity. Cell. 1985; 43(2 Pt 1):531-42. DOI: 10.1016/0092-8674(85)90182-5. View

10.

Lynch D, Miller R . Induction of murine lymphokine-activated killer cells by recombinant IL-7. J Immunol. 1990; 145(6):1983-90. View

11.

Scala G, Quinto I, Ruocco M, Arcucci A, Mallardo M, Caretto P . Expression of an exogenous interleukin 6 gene in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity. J Exp Med. 1990; 172(1):61-8. PMC: 2188154. DOI: 10.1084/jem.172.1.61. View

12.

Alderson M, Sassenfeld H, Widmer M . Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood. J Exp Med. 1990; 172(2):577-87. PMC: 2188337. DOI: 10.1084/jem.172.2.577. View

13.

Fearon E, Pardoll D, Itaya T, Golumbek P, Levitsky H, Simons J . Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell. 1990; 60(3):397-403. DOI: 10.1016/0092-8674(90)90591-2. View

14.

Tohyama K, Lee K, Tashiro K, Kinashi T, Honjo T . Establishment of an interleukin-5-dependent subclone from an interleukin-3-dependent murine hemopoietic progenitor cell line, LyD9, and its malignant transformation by autocrine secretion of interleukin-5. EMBO J. 1990; 9(6):1823-30. PMC: 551887. DOI: 10.1002/j.1460-2075.1990.tb08307.x. View

15.

Davis R, Thomas M, Cameron J, St John T, Scherer S, Padgett R . Rapid DNA isolations for enzymatic and hybridization analysis. Methods Enzymol. 1980; 65(1):404-11. DOI: 10.1016/s0076-6879(80)65051-4. View

16.

Fontana A, Hengartner H, Tribolet N, Weber E . Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol. 1984; 132(4):1837-44. View

17.

KEENE J, Forman J . Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med. 1982; 155(3):768-82. PMC: 2186611. DOI: 10.1084/jem.155.3.768. View

18.

Springer T, Galfre G, Secher D, Milstein C . Mac-1: a macrophage differentiation antigen identified by monoclonal antibody. Eur J Immunol. 1979; 9(4):301-6. DOI: 10.1002/eji.1830090410. View

19.

Morrissey P, Conlon P, Charrier K, Braddy S, Alpert A, Williams D . Administration of IL-7 to normal mice stimulates B-lymphopoiesis and peripheral lymphadenopathy. J Immunol. 1991; 147(2):561-8. View

20.

Colombo M, Ferrari G, Stoppacciaro A, Parenza M, Rodolfo M, Mavilio F . Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med. 1991; 173(4):889-97. PMC: 2190799. DOI: 10.1084/jem.173.4.889. View